clinical trial · NCT06433752
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple SclerosisMultiple SclerosisNo Intervention
brief summary
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
started
Jul 22, 2024
primary completion
Apr 1, 2032
completion
Apr 1, 2032
last updated
May 15, 2026
official title
REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol